Royalty Pharma to Present at Upcoming Investor Conferences
Royalty Pharma (NASDAQ: RPRX) has announced its participation in two major healthcare investor conferences in May 2025. The company will present at the BofA Securities 2025 Healthcare Conference on Wednesday, May 14 at 5:20 p.m. ET, and at the RBC Capital Markets 2025 Global Healthcare Conference on Tuesday, May 20 at 4:05 p.m. ET.
Both presentations will be available via webcast through Royalty Pharma's investor relations website and will remain archived for at least thirty days after the events.
Royalty Pharma (NASDAQ: RPRX) ha annunciato la sua partecipazione a due importanti conferenze per investitori nel settore sanitario previste per maggio 2025. L'azienda terrà una presentazione al BofA Securities 2025 Healthcare Conference mercoledì 14 maggio alle 17:20 ET, e al RBC Capital Markets 2025 Global Healthcare Conference martedì 20 maggio alle 16:05 ET.
Entrambe le presentazioni saranno disponibili in diretta streaming tramite il sito web delle relazioni con gli investitori di Royalty Pharma e resteranno archiviate per almeno trenta giorni dopo gli eventi.
Royalty Pharma (NASDAQ: RPRX) ha anunciado su participación en dos importantes conferencias para inversores del sector salud en mayo de 2025. La compañía realizará una presentación en la BofA Securities 2025 Healthcare Conference el miércoles 14 de mayo a las 5:20 p.m. ET, y en la RBC Capital Markets 2025 Global Healthcare Conference el martes 20 de mayo a las 4:05 p.m. ET.
Ambas presentaciones estarán disponibles vía webcast a través del sitio web de relaciones con inversores de Royalty Pharma y permanecerán archivadas por al menos treinta días después de los eventos.
Royalty Pharma (NASDAQ: RPRX)는 2025년 5월에 열리는 두 개의 주요 헬스케어 투자자 컨퍼런스에 참여할 것임을 발표했습니다. 회사는 5월 14일 수요일 오후 5시 20분(동부시간)에 BofA Securities 2025 Healthcare Conference에서, 5월 20일 화요일 오후 4시 5분(동부시간)에 RBC Capital Markets 2025 Global Healthcare Conference에서 발표를 진행할 예정입니다.
두 발표 모두 Royalty Pharma 투자자 관계 웹사이트를 통해 웹캐스트로 제공되며, 행사 종료 후 최소 30일간 아카이브로 남아 있습니다.
Royalty Pharma (NASDAQ : RPRX) a annoncé sa participation à deux grandes conférences pour investisseurs dans le secteur de la santé en mai 2025. La société présentera lors de la BofA Securities 2025 Healthcare Conference le mercredi 14 mai à 17h20 ET, ainsi qu'à la RBC Capital Markets 2025 Global Healthcare Conference le mardi 20 mai à 16h05 ET.
Les deux présentations seront accessibles en webcast via le site des relations investisseurs de Royalty Pharma et resteront archivées pendant au moins trente jours après les événements.
Royalty Pharma (NASDAQ: RPRX) hat seine Teilnahme an zwei bedeutenden Gesundheitsinvestoren-Konferenzen im Mai 2025 angekündigt. Das Unternehmen wird am BofA Securities 2025 Healthcare Conference am Mittwoch, den 14. Mai um 17:20 Uhr ET und am RBC Capital Markets 2025 Global Healthcare Conference am Dienstag, den 20. Mai um 16:05 Uhr ET präsentieren.
Beide Präsentationen werden per Webcast über die Investor-Relations-Website von Royalty Pharma verfügbar sein und mindestens dreißig Tage nach den Veranstaltungen archiviert bleiben.
- None.
- None.
NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of May:
- BofA Securities 2025 Healthcare Conference on Wednesday, May 14 at 5:20 p.m. ET / 2:20 p.m. PT
- RBC Capital Markets 2025 Global Healthcare Conference on Tuesday, May 20 at 4:05 p.m. ET
The webcasts will be accessible from Royalty Pharma’s “Events” page at https://www.royaltypharma.com/investors/events/. Webcasts will also be archived for a minimum of thirty days.
About Royalty Pharma
Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly – directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Novartis’ Promacta, Pfizer’s Nurtec ODT and Gilead’s Trodelvy, and 15 development-stage product candidates. For more information, visit www.royaltypharma.com.
Royalty Pharma Investor Relations and Communications
+1 (212) 883-6772
ir@royaltypharma.com
